SC5 mAb Represents a Unique Tool for the Detection of Extracellular Vimentin as a Specific Marker of Sézary Cells
- 1 January 2006
- journal article
- Published by The American Association of Immunologists
- Vol. 176 (1), 652-659
- https://doi.org/10.4049/jimmunol.176.1.652
Abstract
Circulating malignant Sézary lymphocytes result from a clonal proliferation of memory/activated CD4+CD45RO+ T lymphocytes primarily involving the skin. Recently, the CD158k/KIR3DL2 cell surface receptor has been identified to phenotypically characterize these cells. We previously described a mAb termed SC5 that identifies an unknown early activation cell membrane molecule. It is expressed selectively by T lymphocytes isolated from healthy individuals upon activation, and by circulating Sézary syndrome lymphocytes. In addition, we found that SC5 mAb was reactive with all resting T lymphocytes once permeabilized, indicating that SC5 mAb-reactive molecule might present distinct cellular localization according to the T cell activation status. In this study, we show for the first time that SC5 mAb recognizes the intermediate filament protein vimentin when exported to the extracellular side of the plasma membrane of viable Sézary malignant cells. We demonstrate that SC5 mAb is unique as it reacts with both viable malignant lymphocytes and apoptotic T cells. As vimentin is also detected rapidly at the cell membrane surface after normal T lymphocyte activation, it suggests that its extracellular detection on Sézary cells could be a consequence of their constitutive activation status. Finally, as a probable outcome of vimentin cell surface expression, autoantibodies against vimentin were found in the sera of Sézary syndrome patients.Keywords
This publication has 26 references indexed in Scilit:
- BCL2 and JUNB abnormalities in primary cutaneous lymphomasBritish Journal of Dermatology, 2004
- CD158k/KIR3DL2 Is a New Phenotypic Marker of Sezary Cells: Relevance for the Diagnosis and Follow-Up of Sezary SyndromeJournal of Investigative Dermatology, 2004
- Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomasBlood, 2003
- Killer cell immunoglobulin‐like receptor expression delineates in situ Sézary syndrome lymphocytesThe Journal of Pathology, 2002
- Identification of Cell Surface Molecules Characterizing Human Cutaneous T-cell LymphomasLeukemia & Lymphoma, 2002
- Variable CD7 Expression on T Cells in the Leukemic Phase of Cutaneous T Cell Lymphoma (Sézary Syndrome)Journal of Investigative Dermatology, 2001
- Intracellular Trafficking of CTLA-4 and Focal Localization Towards Sites of TCR EngagementImmunity, 1996
- Lymphocyte activation: T-cell regulation by CTLA-4Current Biology, 1996
- CD7-positive Sézary syndrome with a Th1 cytokine profileJournal of the American Academy of Dermatology, 1996
- Dicing with death: dissecting the components of the apoptosis machineryTrends in Biochemical Sciences, 1994